Indication

Pure red cell aplasia

Pure red cell aplasia is a rare hematologic syndrome characterized by a profound failure of erythropoiesis that selectively impacts the red blood cell lineage while preserving normal granulopoiesis and megakaryopoiesis. Read more about Pure red cell aplasia

145 drugs 92 manufacturers

Advertisement

Drugs that treat it

Common Pure red cell aplasia therapies.

Showing 55–63 of 145 drugs

Filter & compare in the drug finder →Opens the drug finder with Pure red cell aplasia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Pure red cell aplasia.

Pure red cell aplasia is a rare hematologic syndrome characterized by a profound failure of erythropoiesis that selectively impacts the red blood cell lineage while preserving normal granulopoiesis and megakaryopoiesis.

It can manifest in pediatric populations as a congenital disorder, such as Diamond-Blackfan anemia, or in adults as an acquired condition secondary to autoimmune diseases, thymomas, lymphoproliferative disorders, viral infections like parvovirus B19, or adverse drug reactions.

Pathophysiologically driven by immune-mediated, clonal, or direct cytotoxic destruction and maturation arrest of erythroid progenitors, the condition is clinically defined by severe normocytic normochromic anemia, profound reticulocytopenia, and a near-complete absence of erythroblasts in an otherwise cellular bone marrow.

Personalize your experience

Follow Pure red cell aplasia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it